Biotechnology · Healthcare
CEO, Board Member
Equibles does not estimate personal net worth.
Michael Kauffman was last confirmed as CEO at Karyopharm Therapeutics Inc. (KPTIQ) in a filing dated April 8, 2022. Earlier roles on record: Board Member at Karyopharm Therapeutics Inc. (KPTIQ) until March 22, 2022. Karyopharm Therapeutics Inc. reported in an 8-K filed March 29, 2022 that Michael Kauffman resigned as Board of Directors, effective March 22, 2022. The same filing states: “You acknowledge your resignation from the Company’s Board of Directors effective March 22, 2022, and you affirm that such decision was not because of a disagreement with the Company.” The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $3,069,589 for Michael Kauffman in fiscal 2021, including a base salary of $474,375. Disclosed compensation is on record for 4 fiscal years. Michael Kauffman has spoken on 5 earnings calls across 1 company, most recently for Karyopharm Therapeutics Inc. on May 3, 2021. The companies whose calls Michael Kauffman spoke on are classified in the Healthcare sector.
“You acknowledge your resignation from the Company’s Board of Directors effective March 22, 2022, and you affirm that such decision was not because of a disagreement with the Company.”
“Let me begin first by saying how thrilled I am to also be joined here today with Richard Paulson, our company's new CEO. And we'll begin on slide four. Dr. Sharon Shacham and I started Karyopharm over 12 years ago.”
“2020 was a pivotal year for Karyopharm and I'm extremely proud of the significant progress our team has made towards our commercial, clinical development, and operational objectives, with the ultimate goal of having a positive impact on the lives of patients battling cancer.”
“I'm pleased to report that Karyopharm has continued to make tremendous progress so far in 2020 with the achievement of numerous commercial pipeline and operational accomplishments, positioning us well for what we believe to be continued and sustained future growth.”
“Before I specifically review Karyopharm's performance in the second quarter, I'd like to put into some context where Karyopharm is on its journey to becoming a leading global oncology-focused pharmaceutical company.”
“Despite these challenging times, I just want to share a couple of thoughts that I'm extremely proud to be part of this organization. It has been a remarkable several months now.”
Start not stated–2022-04-08
Last confirmed by a filing; no departure on record
Start not stated–2022-03-22
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Karyopharm Therapeutics Inc. (KPTIQ) | M.D., Ph.D. | $474,375 | $3,069,589 |
| 2020 | Karyopharm Therapeutics Inc. (KPTIQ) | M.D., Ph.D. Chief Executive Officer | $625,624 | $3,937,039 |
| 2019 | Karyopharm Therapeutics Inc. (KPTIQ) | M.D., Ph.D. Chief Executive Officer | $566,500 | $3,231,504 |
| 2018 | Karyopharm Therapeutics Inc. (KPTIQ) | M.D., Ph.D. Chief Executive Officer | $550,000 | $2,274,945 |
“You acknowledge your resignation from the Company’s Board of Directors effective March 22, 2022, and you affirm that such decision was not because of a disagreement with the Company.”
Karyopharm Therapeutics Inc. (KPTIQ)